• Partek Software Has Record Year of Scientific Citations

    February 9, 2016
    The number of scientific journals citing Partek® analysis software has grown each year with 2015 marking a record 930 citations, bringing the total to over 5,000. Among recent citations are those featured in high-impact journals such as Nature, Nature Genetics and Blood to name a few. Topics include cancer genomics, neurodegenerative diseases, developmental biology and biomarker research.
     
  • CASE STUDY: Researchers Discover Potential Diagnostic Tool for Alzheimer’s Disease with Help of Partek Software

    September 8, 2015

    As the world population ages, Alzheimer’s disease will become a significant socio-economic burden to the health care system. That’s why Dr. Lesley Cheng of La Trobe University, who recently moved from The University of Melbourne, set out to identify the disease specific exosomal microRNA (miRNA) biomarkers associated with Alzheimer’s disease (AD) in serum using deep-sequencing technology. 

  • Kennedy Krieger Institute and Partek Incorporated Enter Third Year of NIH/SBIR Grant

    June 30, 2015

    Partek Incorporated in collaboration with the Kennedy Krieger Institute move into the third year of a $1.8M National Institutes of Health (NIH) SBIR grant aimed at developing commercial software to analyze human genetic changes that illuminate chromosomal abnormalities underlying conditions such as autism spectrum disorder (ASD), bipolar disorder, and schizophrenia.

  • Partek Milestone: Cited in Over 3,000 Peer-reviewed Articles

    February 18, 2015

    Partek Incorporated has reached a milestone by having its software cited in over three thousand peer-reviewed scientific publications including prestigious publications such as New England Journal of Medicine, Cell, and Nature. 

  • Partek Flow 4.0 Software Brings More Statistical Power, Visualization, and Speed to NGS Analysis

    January 21, 2015

    Partek Incorporated announces the newest release of their popular analysis software, Partek Flow 4.0. With new features including multi-factor mixed model ANOVA, Fisher’s exact test, and additional visualizations, Partek Flow is an ideal analysis solution for researchers performing next generation sequencing (NGS) based studies. 

  • News of Note: Partek® Flow® 4.0 for NGS Analysis Now Shipping

    January 20, 2015

    Partek Flow 4.0 is now shipping and delivers new analyses, visualizations, and features that reveal the biological meaning of your RNA-Seq data quicker and easier than ever before. We’re pretty excited about these features and think you will be too. Take a peek.

  • Recent Publications: Selected List

    January 20, 2015

    Researchers around the world are using Partek software to make biological discoveries. To date, approximately 3,000 peer-reviewed articles using Partek software have been published.

    RNA-Seq

  • RNA-Seq Analysis Pipeline for Ion Torrent™ Data

    January 20, 2015

    Do you have RNA sequencing data from an Ion Torrent machine? Then download the Whole Transcriptome analysis pipeline for Ion Torrent and load it into your Partek Flow instance. We partnered with Ion Torrent to pinpoint the ideal analysis settings and have stored them in this pipeline to make your analysis process simple and painless.

  • Partek® Genomics Suite® Now Supports 64-bit Mac OS X Mavericks

    January 20, 2015

    We’re pleased to announce that Partek Genomics Suite now supports operating systems that use 64-bit functionality such as Mac OS X Mavericks and Yosemite. This added support will allow better speed and functionality for large-scale studies as well as offer the native look and feel of the operating system on which it runs.

  • Researchers at Queen’s University of Belfast Use Partek Software in First Steps Toward Therapies for Chronic Kidney Disease

    January 18, 2015

    Large, genome-wide quantitative evaluation of DNA methylation associated with chronic kidney disease (CKD) reveals several genes with strong biological evidence for differential methylation. RNA-Seq analysis was performed using Partek® Flow® and Partek® Genomics Suite® to confirm the functional role of differential methylation in ELMO1 and PRKAG2. Findings were validated by functional enrichment using Partek® Pathway™. These results could be the first step toward identifying epigenetic therapies for CKD. 

Pages